

# PROVIDER Update



## Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 2nd Quarter 2019

Approved updates are effective June 30, 2019

On April 16, 2019, the Health Net\* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective June 30, 2019, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- DOFR categories for eight new injectable medications (that can be billed using 10 HCPCS codes).
- HCPCS code changed for one injectable medication.
- Addition of secondary category for 10 existing injectable medications.

### ADDITIONAL INFORMATION

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website at [provider.healthnet.com](http://provider.healthnet.com).

Providers are encouraged to access Health Net's provider portal online at [provider.healthnet.com](http://provider.healthnet.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at [provider\\_services@healthnet.com](mailto:provider_services@healthnet.com) within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.

### THIS UPDATE APPLIES TO CAL MEDICONECT PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)  
Los Angeles County – 1-855-464-3571  
San Diego County – 1-855-464-3572  
[www.healthnet.com](http://www.healthnet.com)

### PROVIDER COMMUNICATIONS

[provider\\_communications@healthnet.com](mailto:provider_communications@healthnet.com)

\* Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments.

## ADDITIONS TO INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

### New Drugs:

| HCPCS        | Drug Name    | Generic Name  | Primary Category | Secondary Category |
|--------------|--------------|---|------------------|--------------------|
| J3590        | Cablivi®     | Caplacizumab-yhdp   | Self-injectable  |                    |
| J3490        | Clorotekal®  | Chloroprocaine hydrochloride injection, for intrathecal use                         | Therapeutic inj  |                    |
| J9999        | Elzonris™    | Tagraxofusp-erzs injection, for intravenous use                                     | Therapeutic inj  | Chemotherapy       |
| 90739        | Hepelisav-b® | Hepatitis B vaccine (recombinant), adjuvanted] solution for intramuscular injection | Therapeutic inj  | Immunizations      |
| J3590        | Nuzyra™      | Omadacycline for injection  | Therapeutic inj  |                    |
| C9399, J3590 | Revcovi™     | Elapegademase-lvlr injection, for intramuscular use                                 | Therapeutic inj  |                    |
| J3590        | Ultomiris™   | Ravulizumab-cwvz injection, for intravenous use                                     | Therapeutic inj  |                    |
| J3490        | Xerava™      | Eravacycline dihydrochloride injection, for intravenous use                         | Therapeutic inj  |                    |

## UPDATES/CHANGES TO INJECTABLE MEDICATION PROCEDURE CODES OR MEDICATIONS

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

### Updates:

| HCPCS | Drug Name | Generic Name       | Comment            |
|-------|-----------|--------------------|--------------------|
| J7329 | Trivisc™  | Sodium hyaluronate | Changed from J3490 |

## CATEGORY CHANGES TO HCPCS CROSSWALK

Secondary category additions were made to the HCPCS crosswalk for the following existing injectable medications.

### Category Changes:

| HCPCS | Drug Name | Generic Name                                   | Primary Category | Secondary Category     |
|-------|-----------|--|------------------|------------------------|
| J0714 | Avycaz®   | Ceftazidime-avibactam Injection                | Therapeutic inj  | Home health/infusion** |
| J1743 | Elaprase® | Idursulfase, 1 mg                              | Therapeutic inj  | Home health/infusion** |
| J3380 | Entyvio™  | Vedolizumab for injection, for intravenous use | Therapeutic inj  | Home health/infusion** |

**CATEGORY CHANGES TO HCPCS CROSSWALK, continued**

| HCPCS        | Drug Name   | Generic Name                                      | Primary Category | Secondary Category     |
|--------------|-------------|---|------------------|------------------------|
| Q5109        | Ixifi™      | Infliximab-qbtx, biosimilar, 10 mg                | Therapeutic inj  | Home health/infusion** |
| J2480        | Kanuma™     | Sebelipase alfa injection, for intravenous use    | Therapeutic inj  | Home health/infusion** |
| C9399, J9999 | Poteligeo®  | Mogamulizumab-kpkc injection, for intravenous use | Therapeutic inj  | Chemotherapy*          |
| J3358        | Stelara® iv | Ustekinumab, for intravenous injection, 1 mg      | Therapeutic inj  | Home health/infusion** |
| J2185        | Vabomere™   | Meropenem-vaborbactam for IV soln                 | Therapeutic inj  | Home health/infusion** |
| J1322        | Vimizim®    | Elosulfase alfa                                   | Therapeutic inj  | Home health/infusion** |
| C9399, J3490 | Zemdri™     | Plazomicin injection, for intravenous use         | Therapeutic inj  | Home health/infusion** |

\*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

\*\*When administered by a nurse in a home setting.